On Tuesday, D. Boral (OTC:BOALY) Capital initiated coverage on Avita Medical Ltd . (NASDAQ: NASDAQ:RCEL) with a Buy rating and a $25.00 price target, representing over 100% upside from the current trading price of $11.75. According to InvestingPro data, analysts maintain a strong bullish consensus on the stock, with price targets ranging from $11.38 to $20.94.
The firm's analysis suggests a strong growth trajectory for Avita Medical (TASE:PMCN), underpinned by its innovative tissue regeneration technology. The platform, known as Recell, has demonstrated encouraging outcomes in clinical trials across various soft tissue and skin conditions, including wounds and burns.
The analyst from D. Boral Capital highlighted the potential for Recell to pave the way for a suite of products, such as PermeaDerm and Cohealyx, designed to manage the full spectrum of soft and deep tissue care. This potential is supported by the company's impressive 32.24% revenue growth and strong gross profit margin of 85.66% in the last twelve months. Avita Medical's market penetration in the United States is the primary focus of the firm's model, with the anticipation of further market expansions.
While current projections are based on U.S. market penetration, the firm acknowledged additional potential for growth. Avita Medical's ongoing endeavors in Europe, the UK, Australia, Japan, and China were noted as promising but not included in the current forecast. These markets are seen as potential upside to the analyst's predictions.
The $25.00 price target set by D. Boral Capital reflects the firm's confidence in Avita Medical's prospects over the next 12 months. This valuation is based on the anticipated success and adoption of Recell and related products in the healthcare market, specifically for tissue-related treatments. With a market capitalization of $65.7 million and an overall "FAIR" financial health rating from InvestingPro, investors should note that while the company shows promise, it's currently operating with negative earnings and rapidly utilizing its cash reserves.
The coverage initiation by D. Boral Capital comes as Avita Medical continues to expand its presence in the medical technology sector, with its stock now under the watch of investors following the firm's positive outlook. For deeper insights into Avita Medical's financial health and growth prospects, investors can access 8 additional exclusive ProTips and comprehensive valuation metrics through InvestingPro, including detailed analysis of the company's cash flow position and market performance metrics.
In other recent news, Avita Medical has been gaining attention in the healthcare sector. The company's RECELL GO Mini, a device designed for treating smaller wounds, has received premarket approval from the FDA, marking a significant milestone. This miniaturized version of the existing RECELL GO device is anticipated to expand Avita Medical's market reach within its full thickness skin defect indication and meet the previously unaddressed need for treatment options for smaller wounds. Following this approval, Cantor Fitzgerald reaffirmed its Overweight rating for Avita Medical and a price target of $21.00.
Avita Medical has reported strong revenue growth of 32% over the past year, with the RECELL GO platform now representing 75% of the company's revenue. In their Third Quarter 2024 Earnings Call, they announced a 29% increase in commercial revenue from the previous quarter, reaching $19.5 million, indicating a robust growth of 44% year-over-year. Despite a net loss for the quarter, the company is progressing towards achieving cash flow break-even and GAAP profitability by Q3 2025.
These recent developments indicate Avita Medical's continued strides in the healthcare sector, with the company poised to introduce the RECELL GO Mini across relevant medical centers during the first quarter of 2025. This move is seen as a step towards solidifying Avita Medical's presence in the wound care market and expanding its customer base.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.